Company news

Castle Biosciences, Inc. news in 2020

Castle Biosciences, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Castle Biosciences Announces Early Repayment of Debt

December 21, 2020

Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 17, 2020

Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock

December 14, 2020

Castle Biosciences Announces Commencement of Proposed Public Offering of Common Stock

December 13, 2020

Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma

December 3, 2020

Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pigmented Lesions

November 16, 2020

Castle Biosciences Announces Third Quarter 2020 Results

November 8, 2020

Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma

November 1, 2020

Castle Biosciences to Present Data at the American Society of Dermatopathology (ASDP) 57th Virtual Annual Meeting

October 28, 2020

Castle Biosciences to Release Third Quarter 2020 Financial Results and Host Conference Call on Monday, November 9, 2020

October 25, 2020

Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma

October 7, 2020

Castle Biosciences Announces Commercial Launch of DecisionDx-SCC

September 1, 2020

Castle Biosciences Announces Leadership Promotions and New Medical Director

August 31, 2020

Castle Biosciences Announces Second Quarter 2020 Results

August 9, 2020

Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma

July 14, 2020

Castle Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock

July 1, 2020

Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock

June 23, 2020

Castle Biosciences Announces Proposed Underwritten Public Offering of Common Stock

June 21, 2020

Castle Biosciences Announces Change of Location of Annual Meeting of Stockholders to Be Held June 4, 2020

May 21, 2020

New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions

May 18, 2020

Castle Biosciences Announces First Quarter 2020 Results

May 10, 2020

Castle Biosciences Announces Publication of a Study Evaluating Incorporation of DecisionDx-SCC into Management of High-Risk Cutaneous Squamous Cell Carcinoma

May 4, 2020

Castle Biosciences Announces Publication of Validation Study for DecisionDx-SCC, Showing this Test is an Independent Predictor of Metastatic Risk in Squamous Cell Carcinoma

April 28, 2020

Castle Biosciences to Release First Quarter 2020 Financial Results and Host Conference Call on Monday, May 11, 2020

April 26, 2020

Castle Biosciences Appoints Miles Harrison to Board of Directors

April 1, 2020

Castle Biosciences Announces Publication of a Systematic Review and Meta-Analysis Demonstrating DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk

March 31, 2020

Castle Biosciences Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma

March 25, 2020

Castle Biosciences Announces Fourth Quarter and Full-Year 2019 Results

March 9, 2020

Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma

March 4, 2020

Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020

February 24, 2020

Castle Biosciences Announces Study Establishing the Value of Integrating DecisionDx-SCC Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma

January 19, 2020

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019

January 8, 2020

Decks in 2020